proglumide has been researched along with Pancreatic Neoplasms in 22 studies
Proglumide: A drug that exerts an inhibitory effect on gastric secretion and reduces gastrointestinal motility. It is used clinically in the drug therapy of gastrointestinal ulcers.
proglumide : A racemate composed of equal amounts of (R)- and (S)-proglumide. A non-selective CCK antagonist that was used primarily for treatment of stomach ulcers, but has been replaced by newer drugs.
N(2)-benzoyl-N,N-dipropyl-alpha-glutamine : A dicarboxylic acid monoamide obtained by formal condensation of the alpha-carboxy group of N-benzoylglutamic acid with dippropylamine.
Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nude mice bearing SW-1990 pancreatic cancer xenografts were injected with CCK (5, 15, or 25 micrograms/kg) or vehicle twice daily for 20 days." | 5.28 | Cholecystokinin stimulates growth of human pancreatic adenocarcinoma SW-1990. ( Bagheri, S; Kramer, S; Smith, JP; Solomon, TE, 1990) |
| " Clinical symptoms and physical signs, laboratory tests, and adverse reactions were checked every 6 weeks as efficacy/tolerability criteria." | 2.68 | Clinical evaluation and safety of loxiglumide (CCK-A receptor antagonist) in nonresectable pancreatic cancer patients. Italian Pancreatic Cancer Study Group. ( Di Prima, F; Militello, C; Pedrazzoli, S; Sperti, C, 1997) |
| "Pancreatic cancer is extremely resistant to various cancer therapies, however, variety of new therapies for pancreatic cancer have been investigated: (1) immunotherapy including cytokines like TNF, adoptive immunotherapy with lymphokine-activated killer cells or cytotoxic T-lymphocytes, and tumor vaccines using mutated Ki-ras oncoprotein or irradiated tumor cells which were transfected by cytokine genes; (2) gene therapy including transfer of cytokine genes or antisense Ki-ras oncogene, and a combination of gene transfer of herpes simplex virus thymidine kinase and subsequent administration of ganciclovir; (3) differentiation therapy including a quinolinone derivative, vesnarinone; (4) endocrine therapy including cholecystokinin-receptor antagonist, CR1505 or L364,718; (5) heavy water, and etc." | 2.40 | [Newly-developing therapies of pancreatic cancer--immunotherapy, gene therapy, differentiation therapy, endocrine therapy and others]. ( Nio, Y; Tamura, K, 1997) |
| "The incidence of pancreatic cancer appeared significantly (P < 0." | 1.29 | Effect of cholecystokinin analogue caerulein and cholecystokinin antagonist lorglumide on pancreatic carcinogenesis in the rat. ( Alaggio, R; Behboo, R; Khajeturian, E; Militello, C; Pedrazzoli, S; Perasole, A; Rovati, L; Sperti, C, 1994) |
| "Cholecystokinin is thought to be an important factor regulating the growth of human pancreatic cancers." | 1.29 | Loxiglumide (CR1505), a cholecystokinin antagonist, specifically inhibits the growth of human pancreatic cancer lines xenografted into nude mice. ( Fukumoto, M; Hayashi, H; Imamura, M; Kawabata, K; Manabe, T; Masai, Y; Morimoto, H; Nio, Y; Tsubono, M, 1993) |
| "Cholecystokinin and bombesin have been shown to promote pancreatic growth and development of azaserine-induced acidophilic atypical acinar cell nodules in rat pancreas after treatment for 16 weeks." | 1.28 | Effects of cholecystokinin and bombesin on development of azaserine-induced pancreatic tumours in rats: modulation by the cholecystokinin receptor antagonist lorglumide. ( Appel, MJ; Jansen, JB; Lamers, CB; Meijers, M; Rovati, LC; van Garderen-Hoetmer, A; Woutersen, RA, 1992) |
| "Rats treated with cholecystokinin developed more acidophilic atypical acinar cell nodules, adenomas and adenocarcinomas than control animals." | 1.28 | Role of cholecystokinin in dietary fat-promoted azaserine-induced pancreatic carcinogenesis in rats. ( Appel, MJ; Jansen, JB; Lamers, CB; Meijers, M; Rovati, LC; Sprij-Mooij, D; Van Garderen-Hoetmer, A; Woutersen, RA, 1992) |
| "Camostate caused an increase in growth of the pancreas and a decrease in the number of (pre)neoplastic ductular pancreatic lesions." | 1.28 | Effects of the synthetic trypsin inhibitor camostate on the development of N-nitrosobis(2-oxopropyl)amine-induced pancreatic lesions in hamsters. ( Jansen, JB; Lamers, CB; Meijers, M; Rovati, LC; van Garderen-Hoetmer, A; Woutersen, RA, 1991) |
| "Nude mice bearing SW-1990 pancreatic cancer xenografts were injected with CCK (5, 15, or 25 micrograms/kg) or vehicle twice daily for 20 days." | 1.28 | Cholecystokinin stimulates growth of human pancreatic adenocarcinoma SW-1990. ( Bagheri, S; Kramer, S; Smith, JP; Solomon, TE, 1990) |
| "Cholecystokinin (CCK) has been shown to promote pancreatic growth and azaserine-induced pancreatic carcinogenesis in rats." | 1.28 | Role of cholecystokinin in the development of BOP-induced pancreatic lesions in hamsters. ( Jansen, JB; Lamers, CB; Meijers, M; Rovati, LC; van Garderen-Hoetmer, A; Woutersen, RA, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.55) | 18.7374 |
| 1990's | 19 (86.36) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nadella, S | 1 |
| Burks, J | 1 |
| Al-Sabban, A | 1 |
| Inyang, G | 1 |
| Wang, J | 1 |
| Tucker, RD | 1 |
| Zamanis, ME | 1 |
| Bukowski, W | 1 |
| Shivapurkar, N | 1 |
| Smith, JP | 3 |
| Cooper, TK | 1 |
| McGovern, CO | 1 |
| Gilius, EL | 1 |
| Zhong, Q | 1 |
| Liao, J | 1 |
| Molinolo, AA | 1 |
| Gutkind, JS | 1 |
| Matters, GL | 1 |
| Sperti, C | 2 |
| Militello, C | 2 |
| Rovati, L | 1 |
| Behboo, R | 1 |
| Khajeturian, E | 1 |
| Perasole, A | 1 |
| Alaggio, R | 1 |
| Pedrazzoli, S | 2 |
| Nio, Y | 3 |
| Tsubono, M | 2 |
| Morimoto, H | 2 |
| Kawabata, K | 2 |
| Masai, Y | 2 |
| Hayashi, H | 2 |
| Manabe, T | 2 |
| Imamura, M | 1 |
| Fukumoto, M | 1 |
| Tseng, CC | 1 |
| Baba, N | 1 |
| Hosokawa, Y | 1 |
| Karsenty, L | 1 |
| Hajri, A | 1 |
| Aprahamian, M | 1 |
| Garaud, JC | 1 |
| Doffoël, M | 1 |
| Damgé, C | 1 |
| Watanapa, P | 1 |
| Flaks, B | 1 |
| Oztas, H | 1 |
| Deprez, PH | 1 |
| Calam, J | 1 |
| Williamson, RC | 1 |
| Tomioka, M | 2 |
| Miyazaki, N | 2 |
| Yamamoto, M | 2 |
| Saito, Y | 2 |
| Hirata, M | 1 |
| Itoh, M | 1 |
| Tsuchida, A | 1 |
| Ooishi, H | 1 |
| Hanada, K | 1 |
| Kajiyama, G | 1 |
| Di Prima, F | 1 |
| Tamura, K | 1 |
| Meijers, M | 5 |
| Appel, MJ | 2 |
| van Garderen-Hoetmer, A | 5 |
| Lamers, CB | 6 |
| Rovati, LC | 6 |
| Jansen, JB | 6 |
| Woutersen, RA | 6 |
| Shimazoe, T | 1 |
| Funakoshi, A | 2 |
| Kono, A | 2 |
| Sprij-Mooij, D | 1 |
| Solomon, TE | 1 |
| Bagheri, S | 1 |
| Kramer, S | 1 |
| Seva, C | 1 |
| Scemama, JL | 1 |
| Bastié, MJ | 1 |
| Pradayrol, L | 1 |
| Vaysse, N | 1 |
| Douglas, BR | 1 |
| de Jong, AJ | 1 |
1 review available for proglumide and Pancreatic Neoplasms
| Article | Year |
|---|---|
[Newly-developing therapies of pancreatic cancer--immunotherapy, gene therapy, differentiation therapy, endocrine therapy and others].
Topics: Animals; Benzodiazepinones; Deuterium Oxide; Devazepide; Genetic Therapy; Humans; Immunotherapy; Pan | 1997 |
1 trial available for proglumide and Pancreatic Neoplasms
| Article | Year |
|---|---|
Clinical evaluation and safety of loxiglumide (CCK-A receptor antagonist) in nonresectable pancreatic cancer patients. Italian Pancreatic Cancer Study Group.
Topics: Double-Blind Method; Female; Hormone Antagonists; Humans; Male; Middle Aged; Neoplasm Recurrence, Lo | 1997 |
20 other studies available for proglumide and Pancreatic Neoplasms
| Article | Year |
|---|---|
Dietary fat stimulates pancreatic cancer growth and promotes fibrosis of the tumor microenvironment through the cholecystokinin receptor.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dietary Fats; Female; Fibrosis; Male; Mice; Mice, | 2018 |
Cholecystokinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in mice.
Topics: Animals; Carcinoma in Situ; Cholecystokinin; Disease Progression; Drug Screening Assays, Antitumor; | 2014 |
Effect of cholecystokinin analogue caerulein and cholecystokinin antagonist lorglumide on pancreatic carcinogenesis in the rat.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adenocarcinoma; Animals; Body Weight; Ceruletide; Chi-Square Distr | 1994 |
Loxiglumide (CR1505), a cholecystokinin antagonist, specifically inhibits the growth of human pancreatic cancer lines xenografted into nude mice.
Topics: Animals; Cell Division; Chloroquine; Cholecystokinin; DNA; Esters; Gabexate; Guanidines; Humans; Mic | 1993 |
Inhibitory effects of a cholecystokinin antagonist, loxiglumide (CR-1505), on the growth of freshly separated and xenografted human pancreatic cancer.
Topics: Animals; Carcinoma, Intraductal, Noninfiltrating; Cholecystokinin; DNA, Neoplasm; Dose-Response Rela | 1993 |
Inhibition of growth of a transplanted rat pancreatic acinar carcinoma with CCK-8.
Topics: Animals; Carcinoma; Cell Division; Dose-Response Relationship, Drug; Neoplasm Transplantation; Pancr | 1993 |
Inhibitory effect of a cholecystokinin antagonist on pancreatic carcinogenesis after pancreatobiliary diversion.
Topics: Animals; Azaserine; Biliopancreatic Diversion; Body Weight; Cholecystokinin; Cocarcinogenesis; Male; | 1993 |
[Effect of combined use of CR1505 with UFT for the tumor growth of the subcutaneously transplanted pancreatic cancer in the Syrian golden hamsters].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cholecystokinin; Cricetinae; | 1993 |
Cholecystokinin receptor antagonist, loxiglumide, inhibits invasiveness of human pancreatic cancer cell lines.
Topics: Blotting, Western; Cell Line; Collagenases; Dose-Response Relationship, Drug; Electrophoresis, Polya | 1996 |
Effects of cholecystokinin and bombesin on development of azaserine-induced pancreatic tumours in rats: modulation by the cholecystokinin receptor antagonist lorglumide.
Topics: Animals; Azaserine; Bombesin; Carcinogens; Cholecystokinin; Drug Synergism; Male; Pancreatic Neoplas | 1992 |
[Effects of UFT and loxiglumide (CR1505) on liver metastasis of human pancreatic cancer cell line, KP-1 N in nude mice].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cholecystokinin; Humans; Liv | 1992 |
[Effect of combined use of CR 1505 with UFT on tumor growth of transplanted pancreatic cancer in the Syrian golden hamster: preliminary report].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cholecystokinin; Cricetinae; | 1992 |
Growth inhibition of human pancreatic cancer cells by cholecystokinin receptor antagonist in tissue culture and in nude mice.
Topics: Adenocarcinoma; Animals; Ceruletide; Cholecystokinin; Humans; In Vitro Techniques; Liver Neoplasms; | 1992 |
Role of cholecystokinin in dietary fat-promoted azaserine-induced pancreatic carcinogenesis in rats.
Topics: Animals; Azaserine; Body Weight; Cholecystokinin; Dietary Fats; Liver; Male; Organ Size; Pancreas; P | 1992 |
Effects of the synthetic trypsin inhibitor camostate on the development of N-nitrosobis(2-oxopropyl)amine-induced pancreatic lesions in hamsters.
Topics: Animals; Carcinogens; Carcinoma; Carcinoma in Situ; Cholecystokinin; Cricetinae; Esters; Gabexate; G | 1991 |
Effects of bombesin on the development of N-nitrosobis(2-oxopropyl)amine-induced pancreatic lesions in hamsters.
Topics: Animals; Body Weight; Bombesin; Cholecystokinin; Cricetinae; Liver; Male; Mesocricetus; Nitrosamines | 1991 |
Cholecystokinin stimulates growth of human pancreatic adenocarcinoma SW-1990.
Topics: Adenocarcinoma; Animals; Cholecystokinin; DNA, Neoplasm; Dose-Response Relationship, Drug; Humans; M | 1990 |
Role of cholecystokinin in the development of BOP-induced pancreatic lesions in hamsters.
Topics: Animals; Body Weight; Carcinogens; Cholecystokinin; Cocarcinogenesis; Cricetinae; Male; Nitrosamines | 1990 |
Lorglumide and loxiglumide inhibit gastrin-stimulated DNA synthesis in a rat tumoral acinar pancreatic cell line (AR42J).
Topics: Animals; DNA, Neoplasm; Gastrins; Glutamine; Ornithine Decarboxylase; Pancreatic Neoplasms; Proglumi | 1990 |
Modulation by CR-1409 (lorglumide), a cholecystokinin receptor antagonist, of trypsin inhibitor-enhanced growth of azaserine-induced putative preneoplastic lesions in rat pancreas.
Topics: Animals; Azaserine; Cholecystokinin; Esters; Gabexate; Glutamine; Guanidines; Male; Pancreatic Neopl | 1989 |